BioNTech is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. Its core products include mRNA-based vaccines, notably the COVID-19 vaccine developed in partnership with Pfizer. Major business segments encompass vaccine development, oncology therapies, and research collaborations. The primary revenue source has been from vaccine sales, particularly during the pandemic, although recent financial reports indicate a significant decline in revenue.
The investment profile of BioNTech is more aligned with growth investors, given its focus on innovative therapies and potential for future product development. However, the recent decline in revenue and negative earnings per share suggest increased risk, making it less suitable for conservative investors. The stock may appeal to those with a higher risk tolerance looking for long-term growth opportunities.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-05-12 02:57 | Hold | Sell | scenario_deterioration |
| 2026-05-08 15:29 | — | Hold | Weak fundamentals and negative momentum signal high risk. |
| 2026-05-08 05:27 | Hold | Hold | Компания демонстрирует значительное снижение выручки и отрицательный EPS, что указывает на финансовые трудности. Текущие тренды и высокая волатильность делают инвестиции в BioNTech рискованными. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-05-27 08:43 | UBS | Rating Upgraded | — → 135 | 92.25 |
| 2026-05-21 20:24 | Bernstein | Update | — → 96 | 90.93 |
| 2026-05-06 11:32 | Canaccord Genuity | Target Lowered | 171 → 158 | 95.5 |
